KPTI

Karyopharm Therapeutics Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-02-13

Figures on this page computed 2026-11-08 12:56 UTC

Last close

0.08USD

Market data, 2026-11-04

Except where said otherwise: 10-K for 2025, filed 2026-02-13

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001193125-26-049397
Reported in
USD
- computed
- 10-K for 2025, filed 2026-02-13
The filing itself
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001193125-26-049397
Reported in
USD
- 10-K for 2025, filed 2026-02-13
- 10-K for 2025, filed 2026-02-13
- 10-K for 2025, filed 2026-02-13
- 10-Q for 2025, filed 2026-08-13
- 10-K for 2025, filed 2026-02-13
- 10-Q for 2025, filed 2026-08-13
The filing itself
-134.2%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-049397
Reported in
USD
- 10-K for 2025, filed 2026-02-13
- 10-K for 2025, filed 2026-02-13
The filing itself
-51.6%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-049397
Reported in
USD
- 10-K for 2025, filed 2026-02-13
- 10-K for 2025, filed 2026-02-13
The filing itself
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001193125-26-049397
Reported in
USD
- 10-K for 2025, filed 2026-02-13
- 10-Q for 2025, filed 2026-08-13
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Safety is the furthest below its sector's middle: 0.14 against 0.52 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

1.48x

1.29x

0.62x

n/a

0.00x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-04

Each against its own average

4 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-02-13

Sales1.48x
Its own average over 10 years, 98.5M.
Profit1.29x
Its own average over 10 years, -151.8M.
Free cash flow0.62x
Its own average over 10 years, -122.4M.
Debtn/a
Its own average over 1 year, 180.6M.
Price0.00x
Its own average over 11 years, 109. Market data, 2026-11-04

Price is furthest from its own average, at 0.00 times.

Sales is 1.48 times its own 10-year average; Profit is 1.29 times its own 10-year average; Free cash flow is 0.62 times its own 10-year average; Price is 0.00 times its own 11-year average.

Every figure in this lens

Except where said otherwise: 10-K for 2025, filed 2026-02-13

Sales against its own 10-year average1.48
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-049397
Reported in
USD
The filing itself
Profit against its own 10-year average1.29
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-049397
Reported in
USD
The filing itself
Free cash flow against its own 10-year average0.62
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-049397
Reported in
USD
The filing itself
Debt against its own 1-year averagen/a
Not held.
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-049397
Reported in
USD
The filing itself
Price against its own 11-year average0.001Market data, 2026-11-04
Source
market
Taken on
2026-11-04
Reported in
USD